|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07F 9/12 | (2006.01) |
| C07F 9/65586 | (2013.01) | ||
| A61K 31/661 | (2006.01) | ||
| C07D 311/30 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07D 311/22 | (2013.01) | ||
| C07D 405/04 | (2013.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 31/38 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Patento numeris | 4086264 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 22166479.0 |
| Europos patento paraiškos padavimo data | 2016-05-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2022-11-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-10-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201562163188 P | 2015-05-18 | US |
| (72) |
Siddiqui-Jain, Adam , US
Bearss, David J. , US
|
| (73) |
Sumitomo Pharma Oncology, Inc. ,
84 Waterford Drive, Marlborough, MA 01752,
US
|
| (54) | ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY |
| ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY |